Plenty of CRISPR pie

While the impending CRISPR patent fight makes for a good spectator sport, many players in the space think it could turn out to be a side story in terms of who gets the technology's big winnings in the long run.

In fact, given the speed of innovation and the breadth of possible uses for the genome editing platform, several patent attorneys and drug developers who spoke with BioCentury think there will be plenty of pieces of the CRISPR pie to go around, and expect improvements and advances will outdate the early patents before products based on them even reach the market...